Puma Biotechnology Inc. buy thomasw
Summary
This prediction is currently active. With a performance of -2.31%, the BUY prediction for Puma Biotechnology Inc. by thomasw is down slightly. This prediction currently runs until 22.06.25. The prediction end date can be changed by thomasw at any time. thomasw has 50% into this predictionPuma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Performance without dividends (%)
Name | 1w |
---|---|
Puma Biotechnology Inc. | -4.837% |
iShares Core DAX® | 1.175% |
iShares Nasdaq 100 | 1.232% |
iShares Nikkei 225® | 1.563% |
iShares S&P 500 | 0.034% |
According to thomasw what are the pros and cons of Puma Biotechnology Inc. for the foreseeable future?
Pros
Cons
Comments by thomasw for this prediction
In the thread Puma Biotechnology Inc. diskutieren
Stopped prediction by thomasw for Puma Biotechnology Inc.
Puma Biotechnology Inc.
09.07.23
09.07.24
24.07.23
Puma Biotechnology Inc.
04.09.22
04.09.23
18.09.22
Puma Biotechnology Inc.
12.12.21
12.12.22
25.12.21